Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3641899 | 0.89 | ADORA3 (0.47) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL724837 | 0.83 | ADORA2A (0.58) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL5964634 | 0.83 | ADORA2A (0.51) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL4064085 | 0.82 | ADORA3 (0.42) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL2778893 | 0.81 | PRKACA (0.41) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL2295172 | 0.80 | ADORA2A (0.65) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL8109955 | 0.78 | ADORA2A (0.64) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL1081737 | 0.77 | ADORA2A (0.68) | ADORA3ADORA2AADORA1ADORA2B | |
| Hydrochloric Acid SCHEMBL6754869 | 0.76 | ADORA2A (0.68) | ADORA3ADORA2AADORA1ADORA2B | |
| Hydrochloric Acid SCHEMBL2031971 | 0.76 | ADORA2A (0.67) | ADORA3ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638579-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2006-03-29 | — | — | EP | claimed |
| WO-2005003150-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2005-01-13 | — | — | WO | claimed |
| US-20160067271-A1 | Methods And Compositions For Preventing Or Treating Obesity | NORTHEASTERN UNIVERSITY | 2016-03-10 | — | — | US | disclosed |
| US-20100009934-A1 | BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090005358-A1 | Compositions and methods for treating medical conditions | LG CHEM, LTD. (KR) | 2009-01-01 | — | — | US | disclosed |
| US-20080003213-A1 | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels | COMBINATORX, INC. | 2008-01-03 | — | — | US | disclosed |
| EP-1638579-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005003150-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005358-A1 | Compositions and methods for treating medical conditions | ITCH, TSLP, P2RX5 | ADORA3 272/4885ADORA2A 542/4885ADORA1 366/4885 |
| US-20160067271-A1 | Methods And Compositions For Preventing Or Treating Obesity | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA2A 1/4885ADORA1 3/4885 |
| US-20100009934-A1 | BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ADRB1, ADRB2, ADRA2B | ADORA3 22/4885ADORA2A 10/4885ADORA1 14/4885 |
| US-20080003213-A1 | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels | IFNG, IL6, IL36G | ADORA3 159/4885ADORA2A 47/4885ADORA1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.